GOSS stock will likely experience volatility next week on important data releases.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020, which takes place from September 7th through 9th.

Details for presentations related to GB001, an oral DP2 antagonist for eosinophilic asthma and chronic rhinosinusitis (CRS), are as follows:

Session Type: E-Poster Session
Session Title: Clinical and laboratory pharmacology in asthma (Session 109)
Abstract Number: 2922
Poster Code: 1420
Poster Title: GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects
Link: https://goss.bio/2DZOjHT

Session Type: E-Poster Session
Session Title: Clinical and laboratory pharmacology in asthma (Session 109)
Abstract Number: 2915
Poster Number: 1421
Poster Title: GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects
Link: https://goss.bio/2ElKgW8

Session Type: E-Poster Session
Session Title: Asthma science: novel targets and mechanisms (Session 193)
Abstract Number: 2885
Poster Number: 2902
Poster Title: GB001 potently inhibits PGD2 metabolite-induced DP2-mediated cell signaling and eosinophil activation
Link: https://goss.bio/3aDmdxM

Details for a presentation related to GB002, an inhaled PDGFR inhibitor for pulmonary arterial hypertension (PAH), are as follows:

Session Type: E-Poster Session
Session Title: Pathophysiology of pulmonary hypertension (Session 231)
Abstract Number: 2551
Poster Number: 3550
Poster Title: Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Link: https://goss.bio/2ElK60Y

On September 1, 2020, Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborativeā„¢ (Quantum Leap) announced dosing of the first patient with razuprotafib in the I-SPY COVID Trial (NCT04488081), a phase 2 platform trial aimed at improving treatment of acute respiratory distress syndrome (ARDS) in severely ill COVID-19 (adult) patients.

“Finding an effective therapeutic agent to treat patients who get critically ill in response to the COVID-19 infection is of utmost importance regardless of whether we have a vaccine,” said Laura Esserman , the founder of the I-SPY programs. “Our group is focused on screening promising agents and quickly identifying therapies that work. Razuprotafib was selected because of its potential to reverse the lung damage by activating Tie2 and stabilizing the leaky blood vessels that cause some of the damage. This has the potential to prevent death and improve time to recovery, which is what we need for this pandemic and any other that comes along in the future.”

“We are extremely pleased by the rapid progress in study site selection and patient screening in this trial,” said Joseph Gardner, President and Founder. “We believe that razuprotafib has the potential to benefit critically ill COVID-19 patients, and hope to provide additional updates on progress before the end of the year.”

The I-SPY COVID TRIAL, is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative. The goal of the trial is to rapidly screen, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality, and avoid or reduce the duration of mechanical ventilation for critically-ill COVID-19 patients. This study arm will evaluate razuprotafib’s potential to sufficiently stabilize the pulmonary vasculature, in order to slow or prevent the progression of COVID-19 associated pulmonary pathology, decrease the need for ventilator support, and reduce mortality.

On August 11, 2020, Piper Sandler analyst Tyler Van Buren kept his Overweight rating and $30 price target on Gossamer Bio after its Q2 results. The analyst believes that investors should own the stock heading into “several important year-end data readouts”, as success from any of its trials could lead to “significant upside” from the current levels.

On July 14, 2020, Cantor Fitzgerald analyst Eliana Merle raised the firm’s price target on Gossamer Bio to $33 from $25 and kept an Overweight rating on the shares. The analyst thinks GB004 has best-in-class potential as an oral in ulcerative colitis. The analyst sees potential for 200%-400% upside over the next 1-2 years as the company’s underappreciated programs unfold.

finviz dynamic chart for  goss